Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Posaconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | CYP8B1 | Q9UNU6 | 2/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Posaconazole SCHEMBL15180133 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL18857056 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL3959600 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL18496410 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL13575780 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL15948109 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL23871970 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL6946672 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL1455343 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 | |
| Posaconazole SCHEMBL20930912 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCG2ABCB11CYP8B1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14658 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122090921-A | Screening method and application of ATF3 and Importin alpha interaction inhibitor | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-116496265-B | Synthesis method of posaconazole halocyclization intermediate | 浙江海翔药业股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260124224-A1 | USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS | NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (CN) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2003032948-A2 | COMPOSITIONS AND METHODS FOR DELIVERING ANTIBACTERIAL, ANTIFUNGAL AND ANTIVIRAL OINTMENTS TO THE ORAL, NASAL OR VAGINAL CAVITY | MCNEIL-PPC, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-20030072807-A1 | Solid particulate antifungal compositions for pharmaceutical use | BAXTER INTERNATIONAL INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020193369-A1 | Antifungal compounds and uses therefor | PROTEZ PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | claimed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | claimed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002055022-A2 | ACTIVE METABOLITE OF ANTIFUNGAL COMPOUND | MERCK & CO., INC. (US) | 2002-07-18 | — | — | WO | claimed |
| WO-2002036203-A2 | AZOLE CONTAINING COMPOSITIONS WITH ENHANCED ANTIFUNGAL ACTIVITY | INFLUX, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | claimed |